{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:14:00Z","timestamp":1791656040218,"version":"4.3.4"},"reference-count":227,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007813","name":"Center for AIDS Research, University of Washington","doi-asserted-by":"publisher","award":["1P30A142853"],"award-info":[{"award-number":["1P30A142853"]}],"id":[{"id":"10.13039\/100007813","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI068581"],"award-info":[{"award-number":["R01 AI068581"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["KL2 TR 001083"],"award-info":[{"award-number":["KL2 TR 001083"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR 001085"],"award-info":[{"award-number":["UL1 TR 001085"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infection, Genetics and Evolution"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.meegid.2016.08.031","type":"journal-article","created":{"date-parts":[[2016,9,5]],"date-time":"2016-09-05T19:40:58Z","timestamp":1473104458000},"page":"292-307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":301,"special_numbering":"C","title":["HIV-1 drug resistance and resistance testing"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0483-7022","authenticated-orcid":false,"given":"Dana S.","family":"Clutter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bertagnolio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Shafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.meegid.2016.08.031_bb0005","doi-asserted-by":"crossref","first-page":"9864","DOI":"10.1128\/JVI.00915-10","article-title":"Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication","volume":"84","author":"Abram","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2016.08.031_bb0010","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02568-12","article-title":"Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness","author":"Abram","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2016.08.031_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042996","article-title":"HIV-1 genetic diversity and transmitted drug resistance mutations among patients from the North, Central and South regions of Angola","volume":"7","author":"Afonso","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.meegid.2016.08.031_bb9005","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/QAD.0b013e328351f5b2","article-title":"Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis","volume":"26","author":"Ajose","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2016.08.031_bb0020","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1089\/08892220260190308","article-title":"Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure","volume":"18","author":"Antinori","year":"2002","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.meegid.2016.08.031_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049602","article-title":"Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism","volume":"7","author":"Archer","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.meegid.2016.08.031_bb0030","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/00126334-200307010-00007","article-title":"Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection","volume":"33","author":"Ariyoshi","year":"2003","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.meegid.2016.08.031_bb0035","series-title":"Abstract 64., XXV International HIV Drug Resistance Workshop, Boston, USA","article-title":"HIV pre-treatment drug resistance in Mexico: a nationally representative WHO survey","author":"Avila-Rios","year":"2016"},{"key":"10.1016\/j.meegid.2016.08.031_bb0040","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"Baeten","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.meegid.2016.08.031_bb0045","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1177\/135965350601100617","article-title":"HIV-1 subtypes and response to combination antiretroviral therapy in Europe","volume":"11","author":"Bannister","year":"2006","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.meegid.2016.08.031_bb0050","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/jac\/dkr569","article-title":"Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir\/ritonavir as their first protease inhibitor","volume":"67","author":"Barber","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.meegid.2016.08.031_bb0055","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1097\/QAD.0b013e328353b066","article-title":"Lopinavir\/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings","volume":"26","author":"Bartlett","year":"2012","journal-title":"AIDS"},{"issue":"Suppl 2","key":"10.1016\/j.meegid.2016.08.031_bb0060","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/135965350801302S04","article-title":"Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment","volume":"13","author":"Bennett","year":"2008","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.meegid.2016.08.031_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004724","article-title":"Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update","volume":"4","author":"Bennett","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.meegid.2016.08.031_bb0070","unstructured":"Bertagnolio, S., Barcarolo, J., Davis, D.H., Gregson, J., Sigaloff, K.C., Hamers, R.L., Rinke de Wit, T.F., Parkin, N., Jordan, M.R., Group, R.T.S.W., 2016. Assessment of Transmitted HIV Drug Resistance in Resource Limitied Countries, 2004\u20132010. Unpublished."},{"key":"10.1016\/j.meegid.2016.08.031_bb0075","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/infdis\/jir025","article-title":"HIV-1 integrase inhibitor resistance and its clinical implications","volume":"203","author":"Blanco","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0080","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1001\/jama.282.12.1135","article-title":"HIV-1 drug resistance in newly infected individuals","volume":"282","author":"Boden","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.meegid.2016.08.031_bb0085","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/QAI.0b013e31829f05ac","article-title":"Viral load monitoring as a tool to reinforce adherence: a systematic review","volume":"64","author":"Bonner","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.meegid.2016.08.031_bb0090","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/jac\/dkm082","article-title":"Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection","volume":"59","author":"Booth","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.meegid.2016.08.031_bb0095","doi-asserted-by":"crossref","DOI":"10.1089\/aid.2006.0310","article-title":"Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz","volume":"23","author":"Borroto-Esoda","year":"2007","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.meegid.2016.08.031_bb0100","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1468-1293.2006.00379.x","article-title":"HIV-1 reverse transcriptase (RT) genotypic patterns and treatment characteristics associated with the K65R RT mutation","volume":"7","author":"Boucher","year":"2006","journal-title":"HIV Med."},{"key":"10.1016\/j.meegid.2016.08.031_bb0105","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3851\/IMP1749","article-title":"Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient","volume":"16","author":"Boyd","year":"2011","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.meegid.2016.08.031_bb0110","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2352-3018(14)00061-7","article-title":"Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis","volume":"2","author":"Boyd","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.meegid.2016.08.031_bb0115","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1128\/JVI.76.4.1753-1761.2002","article-title":"Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection","volume":"76","author":"Brenner","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2016.08.031_bb0120","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/00002030-200301030-00001","article-title":"A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors","volume":"17","author":"Brenner","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2016.08.031_bb0125","doi-asserted-by":"crossref","first-page":"F9","DOI":"10.1097\/01.aids.0000232228.88511.0b","article-title":"HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture","volume":"20","author":"Brenner","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2016.08.031_bb0130","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1086\/431519","article-title":"Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals","volume":"192","author":"Brumme","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0135","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3851\/IMP1687","article-title":"HIV type-1 drug resistance in treatment-naive patients monitored using minority species assays: a systematic review and meta-analysis","volume":"16","author":"Buckton","year":"2011","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.meegid.2016.08.031_bb0140","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1086\/430709","article-title":"Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection","volume":"41","author":"Campbell","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0145","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1093\/jac\/dkv202","article-title":"Primary resistance to integrase strand-transfer inhibitors in Europe","volume":"70","author":"Casadella","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.meegid.2016.08.031_bb0150","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/01.aids.0000218542.08845.b2","article-title":"Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study)","volume":"20","author":"Castagna","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2016.08.031_bb0155","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study","volume":"210","author":"Castagna","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0160","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1097\/QAD.0000000000000407","article-title":"Simplification to atazanavir\/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results","volume":"28","author":"Castagna","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2016.08.031_bb0165","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/infdis\/jit345","article-title":"Persistence of HIV-1 transmitted drug resistance mutations","volume":"208","author":"Castro","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0170","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1177\/135965350701200814","article-title":"Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS resistance network","volume":"12","author":"Chaix","year":"2007","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.meegid.2016.08.031_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109420","article-title":"A significant reduction in the frequency of HIV-1 drug resistance in Quebec from 2001 to 2011 is associated with a decrease in the monitored viral load","volume":"9","author":"Charest","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.meegid.2016.08.031_bb0180","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/S0140-6736(07)61605-5","article-title":"Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial","volume":"370","author":"Chi","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.meegid.2016.08.031_bb0185","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/QAI.0000000000000312","article-title":"Oligonucleotide ligation assay detects HIV drug resistance associated with virologic failure among antiretroviral-naive adults in Kenya","volume":"67","author":"Chung","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.meegid.2016.08.031_bb0190","doi-asserted-by":"crossref","DOI":"10.1097\/QAI.0000000000000942","article-title":"Response to Therapy in Antiretroviral Therapy-Naive Patients with Isolated Nonnucleoside Reverse-Transcriptase Inhibitor-Associated Transmitted Drug Resistance","author":"Clutter","year":"2016","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.meegid.2016.08.031_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/v8020048","article-title":"Genetic variability of HIV-1 for drug resistance assay development","volume":"8","author":"Clutter","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.meegid.2016.08.031_bb0200","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1126\/science.7824947","article-title":"HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy","volume":"267","author":"Coffin","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.meegid.2016.08.031_bb0205","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(11)60983-5","article-title":"Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial","volume":"378","author":"Cohen","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.meegid.2016.08.031_bb0210","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40265-015-0515-6","article-title":"Modifying antiretroviral therapy in virologically suppressed HIV-1-infected patients","volume":"76","author":"Collins","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.meegid.2016.08.031_bb0215","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1128\/JVI.01349-08","article-title":"Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1","volume":"83","author":"Coutsinos","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2016.08.031_bb0220","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/jac\/dku426","article-title":"Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing","volume":"70","author":"Cozzi-Lepri","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.meegid.2016.08.031_bb0225","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1089\/aid.2007.0173","article-title":"Resistance profile of darunavir: combined 24-week results from the POWER trials","volume":"24","author":"de Meyer","year":"2008","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.meegid.2016.08.031_bb0230","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/jmv.2055","article-title":"Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen","volume":"65","author":"Delaugerre","year":"2001","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.meegid.2016.08.031_bb0235","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/QAD.0b013e3282f3f16d","article-title":"Lopinavir\/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients","volume":"22","author":"Delfraissy","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2016.08.031_bb0240","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1128\/AAC.47.11.3377-3383.2003","article-title":"Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase","volume":"47","author":"Diallo","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2016.08.031_bb0245","first-page":"2339","article-title":"Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study","volume":"68","author":"Dolling","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.meegid.2016.08.031_bb0250","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1093\/jac\/dkv243","article-title":"Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades","volume":"70","author":"Doyle","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.meegid.2016.08.031_bb0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036494","article-title":"Low-cost ultra-wide genotyping using Roche\/454 pyrosequencing for surveillance of HIV drug resistance","volume":"7","author":"Dudley","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.meegid.2016.08.031_bb0260","doi-asserted-by":"crossref","first-page":"19739","DOI":"10.7448\/IAS.17.4.19739","article-title":"Protease mutations emerging on darunavir in protease inhibitor-naive and experienced patients in the UK","volume":"17","author":"El Bouzidi","year":"2014","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.meegid.2016.08.031_bb0265","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/QAI.0b013e3181a9972c","article-title":"Increased detection of HIV-1 drug resistance at time of diagnosis by testing viral DNA with a sensitive assay","volume":"51","author":"Ellis","year":"2009","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.meegid.2016.08.031_bb0270","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1056\/NEJM199512213332502","article-title":"Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party","volume":"333","author":"Eron","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.meegid.2016.08.031_bb0275","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/infdis\/jis750","article-title":"Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study","volume":"207","author":"Eron","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0280","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1097\/QAD.0000000000001145","article-title":"Effectiveness and safety of oral HIV preexposure prophylaxis for all populations","volume":"30","author":"Fonner","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2016.08.031_bb0285","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.str.2007.01.006","article-title":"Hydrophobic sliding: a possible mechanism for drug resistance in human immunodeficiency virus type 1 protease","volume":"15","author":"Foulkes-Murzycki","year":"2007","journal-title":"Structure"},{"key":"10.1016\/j.meegid.2016.08.031_bb0290","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/jac\/dku535","article-title":"Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients","volume":"70","author":"Fourati","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.meegid.2016.08.031_bb0295","first-page":"17","article-title":"Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world","volume":"14","author":"Frentz","year":"2012","journal-title":"AIDS Rev."},{"key":"10.1016\/j.meegid.2016.08.031_bb0300","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.1128\/JVI.74.14.6262-6268.2000","article-title":"Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection","volume":"74","author":"Frost","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2016.08.031_bb0305","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1742-4690-9-63","article-title":"Human immunodeficiency virus gag and protease: partners in resistance","volume":"9","author":"Fun","year":"2012","journal-title":"Retrovirology"},{"key":"10.1016\/j.meegid.2016.08.031_bb0310","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/QAI.0000000000000598","article-title":"Brief report: cobicistat compared with ritonavir as a pharmacoenhancer for atazanavir in combination with emtricitabine\/tenofovir disoproxil fumarate: week 144 results","volume":"69","author":"Gallant","year":"2015","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.meegid.2016.08.031_bb0315","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1086\/598502","article-title":"Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy","volume":"48","author":"Geretti","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0320","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/QCO.0b013e32835a1de7","article-title":"Emerging patterns and implications of HIV-1 integrase inhibitor resistance","volume":"25","author":"Geretti","year":"2012","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069266","article-title":"Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy","volume":"8","author":"Geretti","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.meegid.2016.08.031_bb0330","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/cid\/ciu019","article-title":"Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals","volume":"58","author":"Gonzalez-Serna","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0335","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/QAD.0b013e3283427dcb","article-title":"Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy","volume":"25","author":"Goodman","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2016.08.031_bb0340","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1001\/jama.288.2.181","article-title":"Time trends in primary HIV-1 drug resistance among recently infected persons","volume":"288","author":"Grant","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.meegid.2016.08.031_bb0345","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1097\/QAD.0b013e32835646e0","article-title":"Boosted protease inhibitor monotherapy as a maintenance strategy: an observational study","volume":"26","author":"Guiguet","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2016.08.031_bb0350","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa0803152","article-title":"Maraviroc for previously treated patients with R5 HIV-1 infection","volume":"359","author":"Gulick","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.meegid.2016.08.031_bb0355","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1473-3099(09)70136-7","article-title":"Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis","volume":"9","author":"Gupta","year":"2009","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0360","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1097\/QAD.0b013e3283398216","article-title":"Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays","volume":"24","author":"Gupta","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2016.08.031_bb0365","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S0140-6736(12)61038-1","article-title":"Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis","volume":"380","author":"Gupta","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.meegid.2016.08.031_bb0370","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1473-3099(11)70255-9","article-title":"Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study","volume":"12","author":"Hamers","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0375","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1089\/aid.2005.21.171","article-title":"V3: HIV's switch-hitter","volume":"21","author":"Hartley","year":"2005","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.meegid.2016.08.031_bb0380","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/tmi.12237","article-title":"Durable HIV RNA resuppression after virologic failure while remaining on a first-line regimen: a cohort study","volume":"19","author":"Hoffmann","year":"2014","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.meegid.2016.08.031_bb0385","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1128\/AAC.00204-13","article-title":"Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir","volume":"57","author":"Huang","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2016.08.031_bb0390","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/507312","article-title":"Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia","volume":"194","author":"Hunt","year":"2006","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0395","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1086\/605894","article-title":"Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C","volume":"200","author":"Invernizzi","year":"2009","journal-title":"Journal Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0400","doi-asserted-by":"crossref","first-page":"20166","DOI":"10.1073\/pnas.1110064108","article-title":"Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID","volume":"108","author":"Jabara","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.meegid.2016.08.031_bb0405","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/infdis\/jiq167","article-title":"Differential persistence of transmitted HIV-1 drug resistance mutation classes","volume":"203","author":"Jain","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0410","doi-asserted-by":"crossref","first-page":"11457","DOI":"10.1128\/JVI.01384-15","article-title":"Characterizing the diverse mutational pathways associated with R5-tropic maraviroc resistance: HIV-1 that uses the drug-bound CCR5 coreceptor","volume":"89","author":"Jiang","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2016.08.031_bb0415","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/QAI.0b013e3181b4b18c","article-title":"Impact of amino acid variations in Gag and protease of HIV type 1 CRF01_AE strains on drug susceptibility of virus to protease inhibitors","volume":"52","author":"Jinnopat","year":"2009","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.meegid.2016.08.031_bb0420","unstructured":"Jordan, M.R., Barcarolo, J., Hamers, R.L., Rinke de Wit, T.F., Sigaloff, K.C., Davis, D.H., Gregson, J., Parkin, N., Bertagnolio, S., Group, H.R.A.S., 2016. Surveillance of HIV Drug Resistance in Resource Limited Countries Before and After Initiation of First-line Antiretroviral Treatment, 2006\u20132010. Unpublished."},{"key":"10.1016\/j.meegid.2016.08.031_bb0425","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/QAI.0b013e31802e2940","article-title":"Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy","volume":"44","author":"Karlstrom","year":"2007","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.meegid.2016.08.031_bb0430","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciw382","article-title":"Transmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DC","author":"Kassaye","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0435","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1073\/pnas.0802203105","article-title":"Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection","volume":"105","author":"Keele","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.meegid.2016.08.031_bb0440","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/135965350200700305","article-title":"Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir\/ritonavir therapy","volume":"7","author":"Kempf","year":"2002","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.meegid.2016.08.031_bb0445","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0166-3542(96)00944-8","article-title":"Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins","volume":"31","author":"Keulen","year":"1996","journal-title":"Antivir. Res."},{"key":"10.1016\/j.meegid.2016.08.031_bb0450","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1089\/aid.2014.0031","article-title":"Primer ID informs next-generation sequencing platforms and reveals preexisting drug resistance mutations in the HIV-1 reverse transcriptase coding domain","volume":"31","author":"Keys","year":"2015","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.meegid.2016.08.031_bb0455","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1128\/AAC.00388-07","article-title":"Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients","volume":"51","author":"King","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2016.08.031_bb0460","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/QAD.0000000000000485","article-title":"A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses","volume":"28","author":"Kolomeets","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2016.08.031_bb0465","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1310\/hct1504-218","article-title":"Week 144 resistance analysis of elvitegravir\/cobicistat\/emtricitabine\/tenofovir DF versus atazanavir+ritonavir+emtricitabine\/tenofovir DF in antiretroviral-naive patients","volume":"15","author":"Kulkarni","year":"2014","journal-title":"HIV Clin. Trials"},{"key":"10.1016\/j.meegid.2016.08.031_bb0470","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/civ109","article-title":"Lopinavir\/ritonavir monotherapy as second-line antiretroviral treatment in resource-limited Settings - week 104 analysis of ACTG A5230","author":"Kumarasamy","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0475","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1097\/00002030-199610090-00007","article-title":"Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients","volume":"10","author":"Kuritzkes","year":"1996","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2016.08.031_bb0480","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1086\/528802","article-title":"Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects","volume":"197","author":"Kuritzkes","year":"2008","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0485","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/135965350400900102","article-title":"Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors","volume":"9","author":"Lanier","year":"2004","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.meegid.2016.08.031_bb0490","doi-asserted-by":"crossref","first-page":"6824","DOI":"10.1128\/AAC.01490-15","article-title":"HIV drug resistance testing by high-multiplex \u201cwide\u201d sequencing on the MiSeq instrument","volume":"59","author":"Lapointe","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Pt 5","key":"10.1016\/j.meegid.2016.08.031_bb0495","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1099\/0022-1317-75-5-951","article-title":"Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase","volume":"75","author":"Larder","year":"1994","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.meegid.2016.08.031_bb0500","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3851\/IMP1719","article-title":"Virological characterization of patients failing darunavir\/ritonavir or lopinavir\/ritonavir treatment in the ARTEMIS study: 96-week analysis","volume":"16","author":"Lathouwers","year":"2011","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.meegid.2016.08.031_bb0505","series-title":"Transmitted HIV drug resistance survey in two provinces in Papau New Guinea","author":"Lavu","year":"2015"},{"key":"10.1016\/j.meegid.2016.08.031_bb0510","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1089\/aid.2014.0043","article-title":"Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda","volume":"30","author":"Lee","year":"2014","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.meegid.2016.08.031_bb0515","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/cid\/cis887","article-title":"The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa","volume":"56","author":"Levison","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0520","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1073\/pnas.0306764101","article-title":"Dynamics of HIV-1 recombination in its natural target cells","volume":"101","author":"Levy","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.meegid.2016.08.031_bb0525","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jama.2011.375","article-title":"Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis","volume":"305","author":"Li","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.meegid.2016.08.031_bb0530","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/QAD.0000000000001099","article-title":"Sensitive sentinel mutation screening reveals differential underestimation of transmitted HIV drug resistance among demographic groups","volume":"30","author":"Li","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2016.08.031_bb0535","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/infdis\/jiu233","article-title":"HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial","volume":"210","author":"Liegler","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0540","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1056\/NEJMoa013552","article-title":"Antiretroviral-drug resistance among patients recently infected with HIV","volume":"347","author":"Little","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.meegid.2016.08.031_bb0545","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1128\/JVI.02579-07","article-title":"Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection","volume":"82","author":"Little","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2016.08.031_bb0550","first-page":"112","article-title":"From TMC114 to darunavir: five years of data on efficacy","volume":"15","author":"Llibre","year":"2013","journal-title":"AIDS Rev."},{"key":"10.1016\/j.meegid.2016.08.031_bb0555","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148924","article-title":"Effectiveness of ritonavir-boosted protease inhibitor monotherapy in clinical practice even with previous virological failures to protease inhibitor-based regimens","volume":"11","author":"Lopez-Cortes","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.meegid.2016.08.031_bb0560","series-title":"Pan Degenerate Amplification and Adaptation for Highly Sensitive Detection of ARV Drug Resistance, Conference on Retroviruses and Opportunistic Infections 2016","author":"MacLeod","year":"2015"},{"key":"10.1016\/j.meegid.2016.08.031_bb9000","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(07)61049-6","article-title":"of the Titan study group, Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial","volume":"370","author":"Madruga","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.meegid.2016.08.031_bb0565","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1089\/aid.1996.12.307","article-title":"Forward mutation rate of human immunodeficiency virus type 1 in a T lymphoid cell line","volume":"12","author":"Mansky","year":"1996","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.meegid.2016.08.031_bb0570","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/jmv.10550","article-title":"Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure","volume":"72","author":"Marcelin","year":"2004","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.meegid.2016.08.031_bb0575","doi-asserted-by":"crossref","first-page":"5917","DOI":"10.1128\/AAC.01151-15","article-title":"Characterization of HIV-1 resistance to tenofovir alafenamide in vitro","volume":"59","author":"Margot","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2016.08.031_bb0580","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1128\/AAC.45.6.1836-1842.2001","article-title":"Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors","volume":"45","author":"Masquelier","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2016.08.031_bb0585","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1086\/504693","article-title":"HIV-1 coreceptor use in triple-class treatment experienced patients: Baseline prevalence, correlates, and relationship to enfuvirtide response","volume":"194","author":"Melby","year":"2006","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0590","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1128\/AAC.05487-11","article-title":"Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility","volume":"56","author":"Melikian","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2016.08.031_bb0595","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jac\/dkt316","article-title":"Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing","volume":"69","author":"Melikian","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.meegid.2016.08.031_bb0600","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1097\/QAD.0000000000000397","article-title":"Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients","volume":"28","author":"Metzner","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2016.08.031_bb0605","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1086\/381784","article-title":"Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients","volume":"189","author":"Miller","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0610","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0140-6736(08)61081-8","article-title":"Once-daily atazanavir\/ritonavir versus twice-daily lopinavir\/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48week efficacy and safety results of the CASTLE study","volume":"372","author":"Molina","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.meegid.2016.08.031_bb0615","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(11)60936-7","article-title":"Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial","volume":"378","author":"Molina","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.meegid.2016.08.031_bb0620","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/infdis\/jis613","article-title":"HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status","volume":"206","author":"Mollan","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0625","series-title":"PhenoSense HIV Drug Resistance Assay","author":"Monogram Biosciences","year":"2016"},{"key":"10.1016\/j.meegid.2016.08.031_bb0630","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1097\/QAD.0000000000000768","article-title":"A phylotype-based analysis highlights the role of drug-naive HIV-positive individuals in the transmission of antiretroviral resistance in the UK","volume":"29","author":"Mourad","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2016.08.031_bb0635","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jviromet.2014.09.005","article-title":"Optimization of the oligonucleotide ligation assay for the detection of nevirapine resistance mutations in Zimbabwean Human Immunodeficiency Virus type-1 subtype C","volume":"210C","author":"Mutsvangwa","year":"2014","journal-title":"J. Virol. Methods"},{"issue":"Suppl 2","key":"10.1016\/j.meegid.2016.08.031_bb0640","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/135965350801302S10","article-title":"A novel sequential sampling technique for the surveillance of transmitted HIV drug resistance by cross-sectional survey for use in low resource settings","volume":"13","author":"Myatt","year":"2008","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.meegid.2016.08.031_bb0645","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/01.aids.0000218548.77457.76","article-title":"Effect of baseline protease genotype and phenotype on HIV response to atazanavir\/ritonavir in treatment-experienced patients","volume":"20","author":"Naeger","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2016.08.031_bb0650","first-page":"10","article-title":"Prospective sentinel surveillance of human immunodeficiency virus related drug resistance","author":"National Institute for Communicable Diseases","year":"2016","journal-title":"Commun. Dis. Communiqu\u00e9"},{"key":"10.1016\/j.meegid.2016.08.031_bb0655","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1086\/514056","article-title":"Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo","volume":"176","author":"Nijhuis","year":"1997","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0660","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/01.qai.0000214805.52723.c1","article-title":"Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing","volume":"41","author":"Oette","year":"2006","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.meegid.2016.08.031_bb0665","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/jac\/dks010","article-title":"HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G","volume":"67","author":"Palma","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.meegid.2016.08.031_bb0670","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents"},{"key":"10.1016\/j.meegid.2016.08.031_bb0675","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145962","article-title":"Simplified paper format for detecting HIV drug resistance in clinical specimens by oligonucleotide ligation","volume":"11","author":"Panpradist","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.meegid.2016.08.031_bb0680","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1097\/00126334-200412150-00006","article-title":"Long-term persistence of primary genotypic resistance after HIV-1 seroconversion","volume":"37","author":"Pao","year":"2004","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.meegid.2016.08.031_bb0685","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1128\/JVI.80.10.4971-4977.2006","article-title":"The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations","volume":"80","author":"Parikh","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2016.08.031_bb0690","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1089\/apc.2006.0172","article-title":"Prevalence of drug-resistant and nonsubtype B HIV strains in antiretroviral-naive, HIV-infected individuals in New York State","volume":"21","author":"Parker","year":"2007","journal-title":"AIDS Patient Care STDs"},{"key":"10.1016\/j.meegid.2016.08.031_bb0695","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1056\/NEJMoa1311274","article-title":"Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa","volume":"371","author":"Paton","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.meegid.2016.08.031_bb0700","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1741-7007-11-96","article-title":"Modeling the within-host dynamics of HIV infection","volume":"11","author":"Perelson","year":"2013","journal-title":"BMC Biol."},{"key":"10.1016\/j.meegid.2016.08.031_bb0705","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.meegid.2013.02.002","article-title":"Antiretroviral drug resistance in HIV-1 therapy-naive patients in Cuba","volume":"16","author":"Perez","year":"2013","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.meegid.2016.08.031_bb0710","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1128\/AAC.44.4.920-928.2000","article-title":"A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1","volume":"44","author":"Petropoulos","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2016.08.031_bb0715","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109148","article-title":"Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings","volume":"9","author":"Phillips","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.meegid.2016.08.031_bb0720","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/S2352-3018(14)70021-9","article-title":"Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis","volume":"1","author":"Phillips","year":"2014","journal-title":"Lancet HIV"},{"key":"10.1016\/j.meegid.2016.08.031_bb0725","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1097\/01.aids.0000233569.74769.69","article-title":"HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors","volume":"20","author":"Poveda","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2016.08.031_bb0730","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1089\/aid.2007.0275","article-title":"Effect of baseline viral susceptibility on response to darunavir\/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2","volume":"24","author":"Pozniak","year":"2008","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.meegid.2016.08.031_bb0735","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1093\/jac\/dkr171","article-title":"Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study","volume":"66","author":"Prosperi","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.meegid.2016.08.031_bb0740","first-page":"127","article-title":"Boosted protease inhibitor monotherapy. What have we learnt after seven years of research?","volume":"12","author":"Pulido","year":"2010","journal-title":"AIDS Rev."},{"key":"10.1016\/j.meegid.2016.08.031_bb0745","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1172\/JCI67399","article-title":"Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance","volume":"123","author":"Rabi","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.meegid.2016.08.031_bb0750","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study","volume":"381","author":"Raffi","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.meegid.2016.08.031_bb0755","series-title":"National Consolidated Guidelines for the Prevention of Mother-to-child Transmission of HIV (PMTCT) and the Management of HIV in Children, Adolescents, And Adults","author":"Republic of South Africa Department of Health","year":"2014"},{"key":"10.1016\/j.meegid.2016.08.031_bb0760","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.0030087","article-title":"HIV-1 subtype B protease and reverse transcriptase amino acid covariation","volume":"3","author":"Rhee","year":"2007","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.meegid.2016.08.031_bb0765","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1086\/600073","article-title":"Predictive value of HIV-1 genotypic resistance test interpretation algorithms","volume":"200","author":"Rhee","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0770","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1128\/AAC.00574-10","article-title":"HIV-1 protease mutations and protease inhibitor cross-resistance","volume":"54","author":"Rhee","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2016.08.031_bb0775","article-title":"Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis","volume":"12","author":"Rhee","year":"2015","journal-title":"PLoS Med."},{"key":"10.1016\/j.meegid.2016.08.031_bb0780","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145772","article-title":"HIV-1 drug resistance mutations: potential applications for point-of-care genotypic resistance testing","volume":"10","author":"Rhee","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.meegid.2016.08.031_bb0785","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00495-16","article-title":"HIV-1 protease, reverse transcriptase, and integrase variation","author":"Rhee","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2016.08.031_bb0790","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0b013e31823df4da","article-title":"Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis","volume":"59","author":"Rimsky","year":"2012","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.meegid.2016.08.031_bb0795","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/QAI.0b013e31828ace69","article-title":"Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir\/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK","volume":"63","author":"Rockstroh","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.meegid.2016.08.031_bb0800","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1758-2652-14-24","article-title":"The net cost of incorporating resistance testing into HIV\/AIDS treatment in South Africa: a Markov model with primary data","volume":"14","author":"Rosen","year":"2011","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.meegid.2016.08.031_bb0805","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/nm.2892","article-title":"Antiretroviral dynamics determines HIV evolution and predicts therapy outcome","volume":"18","author":"Rosenbloom","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.meegid.2016.08.031_bb0810","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1468-1293.2008.00644.x","article-title":"Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naive, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227","volume":"9","author":"Ruxrungtham","year":"2008","journal-title":"HIV Med."},{"key":"10.1016\/j.meegid.2016.08.031_bb0815","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/cid\/ciu020","article-title":"Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels","volume":"58","author":"Santoro","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0820","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/cid\/cir669","article-title":"Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B","volume":"53","author":"Scherrer","year":"2011","journal-title":"Clinical Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0825","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1097\/QAD.0000000000000708","article-title":"HIV resistance testing and detected drug resistance in Europe","volume":"29","author":"Schultze","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2016.08.031_bb0830","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/S0140-6736(13)61164-2","volume":"381","author":"Second-Line Study Group","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.meegid.2016.08.031_bb0835","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/81407","article-title":"Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries","volume":"6","author":"Shafer","year":"2000","journal-title":"Nat. Med."},{"issue":"Suppl 2","key":"10.1016\/j.meegid.2016.08.031_bb0840","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/135965350801302S13","article-title":"Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies","volume":"13","author":"Shafer","year":"2008","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.meegid.2016.08.031_bb0845","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1128\/AAC.00592-09","article-title":"Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations","volume":"53","author":"Shahriar","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2016.08.031_bb0850","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/01.qai.0000219290.49152.6a","article-title":"Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience","volume":"41","author":"Shet","year":"2006","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.meegid.2016.08.031_bb0855","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.coviro.2013.08.007","article-title":"Recent trends in HIV-1 drug resistance","volume":"3","author":"Siliciano","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.meegid.2016.08.031_bb0860","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1097\/00002030-200207260-00008","article-title":"Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals","volume":"16","author":"Simon","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2016.08.031_bb0865","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118145","article-title":"High prevalence of the K65R mutation in HIV-1 subtype c infected patients failing tenofovir-based first-line regimens in South Africa","volume":"10","author":"Skhosana","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.meegid.2016.08.031_bb0870","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.virusres.2008.01.002","article-title":"Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors","volume":"134","author":"Sluis-Cremer","year":"2008","journal-title":"Virus Res."},{"key":"10.1016\/j.meegid.2016.08.031_bb0875","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.antiviral.2014.04.001","article-title":"E138A in HIV-1 reverse transcriptase is more common in subtype C than B: implications for rilpivirine use in resource-limited settings","volume":"107","author":"Sluis-Cremer","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.meegid.2016.08.031_bb0880","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3851\/IMP2780","article-title":"Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007\u20132013","volume":"20","author":"Stekler","year":"2015","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.meegid.2016.08.031_bb0885","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1086\/648090","article-title":"Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211","volume":"200","author":"Su","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0890","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1099\/vir.0.055624-0","article-title":"Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of subtype B human immunodeficiency virus type 1","volume":"95","author":"Sutherland","year":"2014","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.meegid.2016.08.031_bb0895","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/QAI.0b013e3181d0558f","article-title":"Improved detection of CXCR4-using HIV by V3 genotyping: application of population-based and \u201cdeep\u201d sequencing to plasma RNA and proviral DNA","volume":"54","author":"Swenson","year":"2010","journal-title":"J. Acquir. Immune Defic."},{"key":"10.1016\/j.meegid.2016.08.031_bb0900","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1126\/science.1241475","article-title":"Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex","volume":"341","author":"Tan","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.meegid.2016.08.031_bb0905","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11633630-000000000-00000","article-title":"HIV-1 antiretroviral resistance: scientific principles and clinical applications","volume":"72","author":"Tang","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.meegid.2016.08.031_bb0910","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154221","article-title":"Role of rilpivirine and etravirine in efavirenz and nevirapine-based regimens failure in a resource-limited country: a cross-sectional study","volume":"11","author":"Teeranaipong","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.meegid.2016.08.031_bb0915","article-title":"Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study","author":"TenoRes Study","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0920","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1128\/AAC.01668-12","article-title":"HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir","volume":"57","author":"Theys","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"607","key":"10.1016\/j.meegid.2016.08.031_bb0925","first-page":"e601","article-title":"Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine","volume":"21","author":"Theys","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.meegid.2016.08.031_bb0930","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana","volume":"367","author":"Thigpen","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.meegid.2016.08.031_bb0935","author":"UNAIDS"},{"key":"10.1016\/j.meegid.2016.08.031_bb0940","author":"UNAIDS"},{"key":"10.1016\/j.meegid.2016.08.031_bb0945","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067188","article-title":"Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens","volume":"8","author":"Van Zyl","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.meegid.2016.08.031_bb0950","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/QAI.0b013e3181bca669","article-title":"Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors","volume":"52","author":"Varghese","year":"2009","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.meegid.2016.08.031_bb0955","doi-asserted-by":"crossref","DOI":"10.1089\/aid.2016.0038","article-title":"Q148N, a novel integrase inhibitor resistance mutation associated with low-level reduction in elvitegravir susceptibility","author":"Varghese","year":"2016","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.meegid.2016.08.031_bb0960","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/QAD.0b013e32833677ac","article-title":"Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies","volume":"24","author":"Vingerhoets","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2016.08.031_bb0965","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/2325957415596229","article-title":"Five antiretroviral drug class-resistant HIV-1 in a treatment-naive patient successfully suppressed with optimized antiretroviral drug selection","volume":"14","author":"Volpe","year":"2015","journal-title":"J. Int. Assoc. Providers AIDS Care"},{"key":"10.1016\/j.meegid.2016.08.031_bb0970","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1758-2652-13-35","article-title":"A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries","volume":"13","author":"Waning","year":"2010","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.meegid.2016.08.031_bb0975","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1086\/315686","article-title":"Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993\u20131998","volume":"182","author":"Weinstock","year":"2000","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0980","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1086\/420789","article-title":"The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities","volume":"189","author":"Weinstock","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb0985","first-page":"642","article-title":"2014 Update of the drug resistance mutations in HIV-1","volume":"22","author":"Wensing","year":"2014","journal-title":"Top. Antivir. Med."},{"key":"10.1016\/j.meegid.2016.08.031_bb0990","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1128\/JVI.80.10.4909-4920.2006","article-title":"Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir","volume":"80","author":"Westby","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2016.08.031_bb0995","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1128\/JVI.02006-06","article-title":"Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry","volume":"81","author":"Westby","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2016.08.031_bb1000","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1097\/QAD.0b013e3283388742","article-title":"Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006.","volume":"24","author":"Wheeler","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2016.08.031_bb1005","doi-asserted-by":"crossref","first-page":"F41","DOI":"10.1097\/00002030-200210180-00002","article-title":"Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates","volume":"16","author":"Whitcomb","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2016.08.031_bb1010","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1086\/378281","article-title":"Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates","volume":"188","author":"Whitcomb","year":"2003","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb1015","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1128\/AAC.00853-06","article-title":"Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism","volume":"51","author":"Whitcomb","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2016.08.031_bb1020","article-title":"Week 144 resistance analysis of elvitegravir\/cobicistat\/emtricitabine\/tenofovir DF versus efavirenz\/emtricitabine\/tenofovir DF in antiretroviral-naive patients","author":"White","year":"2014","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.meegid.2016.08.031_bb1025","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.3390\/v6072858","article-title":"Resistance analyses of integrase strand transfer inhibitors within phase 3 clinical trials of treatment-naive patients","volume":"6","author":"White","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.meegid.2016.08.031_bb1030","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiw213","article-title":"No evidence that HIV-1 subtype C infection compromises the efficacy of tenofovir-containing regimens: cohort study in the United Kingdom","author":"White","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb1035","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1086\/511035","article-title":"HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211","volume":"44","author":"Wilkin","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb1040","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1172\/JCI4948","article-title":"A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors","volume":"102","author":"Winters","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.meegid.2016.08.031_bb1045","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1473-3099(11)70032-9","article-title":"Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study","volume":"11","author":"Wittkop","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb1050","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1128\/JCM.06689-11","article-title":"Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool","volume":"50","author":"Woods","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.meegid.2016.08.031_bb1055","series-title":"Concept Note: Surveillance of HIV Drug Resistance in Adults Initiating Antiretroviral Therapy (Pre-treatment HIV Drug Resistance) HIV\/AIDS, Geneva, Switzerland","author":"World Health Organization","year":"2014"},{"key":"10.1016\/j.meegid.2016.08.031_bb1060","series-title":"Concept Note: Surveillance of HIV Drug Resistance in Adults Receiving ART, HIV\/AIDS, Geneva, Switzerland","author":"World Health Organization","year":"2014"},{"key":"10.1016\/j.meegid.2016.08.031_bb1065","author":"World Health Organization"},{"key":"10.1016\/j.meegid.2016.08.031_bb1070","author":"World Health Organization"},{"key":"10.1016\/j.meegid.2016.08.031_bb1075","author":"World Health Organization"},{"key":"10.1016\/j.meegid.2016.08.031_bb1080","author":"World Health Organization"},{"key":"10.1016\/j.meegid.2016.08.031_bb1085","author":"World Health Organization"},{"key":"10.1016\/j.meegid.2016.08.031_bb1090","author":"World Health Organization"},{"key":"10.1016\/j.meegid.2016.08.031_bb1095","author":"World Health Organization"},{"key":"10.1016\/j.meegid.2016.08.031_bb1100","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1097\/QAD.0b013e32832d40ad","article-title":"The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection","volume":"23","author":"Yerly","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2016.08.031_bb1105","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3851\/IMP1748","article-title":"Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy","volume":"16","author":"Young","year":"2011","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.meegid.2016.08.031_bb1110","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1128\/JCM.01669-13","article-title":"Simultaneous detection of major drug resistance mutations in the protease and reverse transcriptase genes for HIV-1 subtype C by use of a multiplex allele-specific assay","volume":"51","author":"Zhang","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.meegid.2016.08.031_bb1115","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1128\/JCM.02833-15","article-title":"Simultaneous detection of major drug resistance mutations of HIV-1 subtype B viruses from dried blood spot specimens by multiplex allele-specific assay","volume":"54","author":"Zhang","year":"2016","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.meegid.2016.08.031_bb1120","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/cid\/ciu367","article-title":"Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens","volume":"59","author":"Zheng","year":"2014","journal-title":"Clinical Infect. Dis."},{"key":"10.1016\/j.meegid.2016.08.031_bb1125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095956","article-title":"First line treatment response in patients with transmitted HIV drug resistance and well defined time point of HIV infection: updated results from the German HIV-1 seroconverter study","volume":"9","author":"Zu Knyphausen","year":"2014","journal-title":"PLoS One"}],"container-title":["Infection, Genetics and Evolution"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567134816303690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567134816303690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T07:08:36Z","timestamp":1777619316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567134816303690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":227,"alternative-id":["S1567134816303690"],"URL":"https:\/\/doi.org\/10.1016\/j.meegid.2016.08.031","relation":{},"ISSN":["1567-1348"],"issn-type":[{"value":"1567-1348","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HIV-1 drug resistance and resistance testing","name":"articletitle","label":"Article Title"},{"value":"Infection, Genetics and Evolution","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.meegid.2016.08.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}